Efficacy and safety of calcium channel blockers in heart failure: Focus on recent trials with second-generation dihydropyridines

American Heart Journal

Volumn 139, Issue 2, 2000, Pages 185-194

  De Vries, Rob J M ^b   Van Veldhuisen, Dirk J ^b   Dunselman, Peter H J M ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Ignatius Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; ISRADIPINE; LACIDIPINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; HEADACHE; HUMAN; LEG EDEMA; LUNG EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; VERTIGO;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; EXERCISE TEST; EXERCISE TOLERANCE; FELODIPINE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; VENTRICULAR FUNCTION, LEFT;

EID: 0033973435     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90224-2     Document Type: Article

References (54)

1. Gheorghiade M, Cody RJ, Francis GS, et al. Current medical therapy for advanced heart failure. Am Heart J 1998; 132:S231-48.
2. DEFIANT Research Group. Improved diastolic function with the calcium antagonist nisoldipine (coat.core) in patients post-myocardial infarction: results of the DEFIANT study. Eur Heart J 1992;13:1496-505.
3. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
4. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14:1237-45.
5. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
6. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind crossover study to compare the efficacy and safely of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
7. Jezek V, Jezkova J, Michaljanic A, et al. Long-term effects of isosorbide dinitrate and nifidepine, singly and in association, in patients with chronic heart failure. Eur Heart J 1990; 11:200-6.
8. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
9. Packer M. Calcium channel blockers in chronic heart failure: the risks of "physiologically rational" therapy. Circulation 1990;82:2254-7.
10. Todd PA, Faulds D. Felodipine: a review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992;44:251-77.
11. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86.
12. Hall ST, Harding SM, Evans GL, et al. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol 1991;[suppl 4]:9-13.
13. Po LW, Zhang WY. What lessons can be learned from withdrawal of mibefradil from the market. Lancet 1998;351:1829-30.
14. Stevenson LW, Perloff J. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8.
15. Franciosa JA, Dunkman B, Leddy CL. Hemodynamic effects of vasodilators and long-term response in heart failure. J Am Coll Cardiol 1984;3:1521-30.
16. Cintron G, Johnsson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87[suppl VI]:17-23.
17. de Vries RJM, Dunselman PHJM, Chin Kon et al. Effects of lacidipine on peak oxygen consumption, neurohormones and invasive hemodynamics in patients with mild to moderate chronic heart failure. Heart 1996;75:159-64.
18. Tuininga YS, van Veldhuisen DJ, Brouwer J, et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 1994;72:509-13.
19. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993;22[suppl A]:179-84.
20. Sara H, Ikenouchi H, Aoyagi T, et al. Acute hemodynamic effects of nivaldipine, a new calcium channel blocker, in patients with congestive heart failure. J Cardiovasc Pharmacol 1990;15:317-22.
21. Schofer J, Hobuss M, Aschenberg W, et al. Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. Eur Heart J 1990;11:712-21.
22. van den Toren EW, van Veldhuisen DJ, van Bruggen A, et al. Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure: a double-blind, placebocontrolled study. Int J Cardiol 1996;53:37-43.
23. Dei Cas L, Metra M, Ferrari R, et al. Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. Cardiovasc Drugs Ther 1993;7:103-10.
24. Gradham AH. Hemodynamic effects of the vascular selective calcium channel antagonist felodipine in patients with impaired left ventricular function. Am Heart J 1992;123:273-8.
25. Walsh JT, Andrews R, Curtis S, et al. Effects of amlodipine in chronic heart failure [abstract]. Eur Heart J 1996;17[suppl A]:459.
26. Smith WB, DeAbate AC, Gollub SB, et al. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure: results of a multicenter randomized, double-blind, placebo-controlled, dose-ranging study [abstract]. Circulation 1994;90[suppl I]:603.
27. Capewell S, Wathen CG, Muir AL. Central and peripheral haemodynamic responses to felodipine in congestive heart failure. Eur J Clin Pharmacol 1991;41:95-8.
28. Kassis A, Amtorp O. Long-term clinical, hemodynamic, angiographic, and neurohumoral response to vasodilation with felodipine in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 1990;15:347-52.
29. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995;73:428-33.
30. Dunselman PHJM, van der Mark TW, Kuntze CE, et al. Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischemic heart disease. Eur Heart J 1990;11:200-6.
31. Cohn JA, Ziesche SM, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997;96:856-63.
32. Abrams J, Bristow MR, Chiang Y, et al. Double-blind evaluation of the safety and efficacy of nicardipine in patients with advanced chronic congestive heart failure [abstract]. J Am Coll Cardiol 1993;21 [suppl A]:377A.
33. Agostini P, Doria E, Riva S, et al. Acute and chronic efficacy of felodipine in congestive heart failure. Int J Cardiol 1991;30:89-95.
34. Gheorghiade M, Hall V, Goldberg AD, et al. Long term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensin converting enzyme inhibitors [abstract]. J Am Coll Cardiol 1991;17[suppl A]27:4A.
35. Gaudron P, Kugler I, Hu K, et al. Long-lerm calcium-channel blockade causes left ventricular dilation in asymptomatic patients with chronic infarction [abstract]. J Am Coll Cardiol 1996;[suppl A]27:774-1.
36. Packer M, Nicod P, Khanderia R, et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure [abstract]. J Am Coll Cardiol 1991;17[suppl A]:274A.
37. Udelsan JE, DeAbate CA, Vijay N, et al. Effect of amlodipine on exercise tolerance and quality of life in mild to moderate heart failure with systolic dysfunction [abstract]. J Am Coll Cardiol 1996;[suppl A]27:774-2.
38. De Vries RJM, Queré M, Lok DJA, et al. Comparison of effects on peak oxygen consumption, quality of life and plasma neurohormones of felodipine and enalapril in patients with congestive heart failure. Am J Cardiol 1995;76:1253-8.
39. Ghali JK, Pressler M, Nye R, et al. Is suppression of the neurohormonal system a prerequisite to improve survival in patients with heart failure and impaired left ventricular systolic function [abstract]? Circulation 1997;95[suppl I]:385.
40. Rousseau MF, Melin J, Benedict CR, et al. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994;15:957-64.
41. Binkley PF, Ahmed S, Nunziata E, et al. Autonomic response to amlodipine differs between ischemic and non-ischemic cardiomyapathy [abstract]. Circulation 1996;94[suppl I]:3645.
42. Binkley PF, Nunziata E, Hatton PS, et al. Dose and circadian dependent autonomic response to vasodilation with amlodipine in congestive heart failure [abstract]. J Am Coll Cardiol 1996;[suppl A]27:774-5.
43. Mohler ER III, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. J Am Coll Cardiol 1997;30:35-41.
44. Pressler ML, Carson PE, Miller AB, et al. Safety of amlodipine in severe heart failure: reduction of sudden death in non-ischemic heart disease [abstract]. J Am Coll Cardiol 1996;[suppl A]27:774-6.
45. Packer M, O'Conner CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) Study Group. Effects of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
46. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996;94:347-52.
47. Liao YH. Interventional study of diltiazem in dilated cardiomyopathy: a report of multiple centre clinical trial in China. Int J Cardiol 1998;64:25-30.
48. Hansen JF. ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Cardiovasc Drugs Ther 1995;9:503-7.
49. Mulder P, Richard V, Compagnon P, et al. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997;29:416-21.
50. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
51. Williams JF, Bristow MR, Fowler MB, et al, for the Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1995;26:1376-98.
52. Carson DA, Ribeiro JM. Apotosis and disease. Lancet 1993;341:1251-4.
53. Massie BM, Cleland JGF, Armstrong PW, et al, for the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. J Card Fail 1998;4:3-8.
54. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. Am Heart J 1998;135:367-72.